About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Pdgfratm12Sor
targeted mutation 12, Philippe Soriano
MGI:3838504
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Pdgfratm12Sor/Pdgfra+
involves: 129 * C57BL/6 MGI:3838615
cn2
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Pdgfratm12Sor/Pdgfra+
involves: 129 * C57BL/6J * SJL MGI:3838621


Genotype
MGI:3838615
cn1
Allelic
Composition
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Pdgfratm12Sor/Pdgfra+
Genetic
Background
involves: 129 * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(cre/ERT)Nat mutation (3 available); any Gt(ROSA)26Sor mutation (942 available)
Pdgfratm12Sor mutation (1 available); any Pdgfra mutation (85 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• 6 months after tamoxifen treatment, mice develop intestinal disease and eventually die or are sacrificed

digestive/alimentary system
• tamoxifen-treated mice exhibit partial or complete fibrosis of the small intestine and cecum unlike in wild-type mice with increased submucosal connective tissue and proportional increase in fibroblast-like cells and collagenous matrix
• tamoxifen-treated mice exhibit partial or complete fibrosis of the small intestine and cecum unlike in wild-type mice with increased submucosal connective tissue and proportional increase in fibroblast-like cells and collagenous matrix
• tamoxifen-treated mice exhibit partial or complete fibrosis of the small intestine and cecum unlike in wild-type mice with increased submucosal connective tissue and proportional increase in fibroblast-like cells and collagenous matrix
• in tamoxifen-treated mice

cardiovascular system
• in tamoxifen-treated mice

renal/urinary system
• sclerotic glomeruli in tamoxifen-treated mice
• in tamoxifen-treated mice
• enlarged glomeruli in tamoxifen-treated mice
• in tamoxifen-treated mice

neoplasm
• at between 44 and 76 weeks of age, 5 of 29 tamoxifen-treated mice develop sarcomas arising from dermis or muscle connective tissue

muscle
• in tamoxifen-treated mice

respiratory system
• around the bronchioles in tamoxifen-treated mice

integument
• in tamoxifen-treated mice




Genotype
MGI:3838621
cn2
Allelic
Composition
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Pdgfratm12Sor/Pdgfra+
Genetic
Background
involves: 129 * C57BL/6J * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2atm1Rdp mutation (6 available); any Cdkn2a mutation (62 available)
Gt(ROSA)26Sortm1(cre/ERT)Nat mutation (3 available); any Gt(ROSA)26Sor mutation (942 available)
Pdgfratm12Sor mutation (1 available); any Pdgfra mutation (85 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• all tamoxifen-treated mice develop sarcomas of the skin or muscle connective tissue after 10 to 19 weeks
• 2 tamoxifen-treated mice develop large intestinal tumors resembling undifferentiated fibrosarcomas

muscle
• tamoxifen-treated mice develop muscle fibrosis at 10 to 19 weeks of age

integument
• tamoxifen-treated mice develop skin fibrosis at 10 to 19 weeks of age

digestive/alimentary system
• after 15 weeks, tamoxifen-treated mice exhibit intestinal fibrosis





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
04/23/2024
MGI 6.23
The Jackson Laboratory